Erythroblastosis, often known as erythroblastosis fetalis or hemolytic disease of the fetus and newborn (HDFN), is a serious condition characterized by the immune-mediated destruction of fetal red blood cells. This occurs when maternal antibodies cross the placenta and target antigens on fetal erythrocytes, leading to anemia, erythroblastosis (excessive immature red blood cells in circulation), and potentially severe fetal complications or death. Detecting and monitoring the molecular markers of erythroblastosis is critical for diagnosis, prognosis, and therapeutic management.
The Erythroblastosis ELISA Kit is an enzyme-linked immunosorbent assay designed for the in vitro quantitative measurement of specific biomarkers relevant to erythroblastosis in biological samples. Generally, ELISA kits for erythroblastosis may target proteins associated with erythroblastosis virus oncogenes (such as ETS family proteins) or hemolytic disease markers, depending on the kit's design and application.
Applications
- Quantitative detection of proteins linked to erythroblastosis or related viral oncogenes in tissue homogenates, plasma, serum, or body fluids.
- Research into the pathophysiology of erythroblastosis fetalis and associated immune responses.
- Clinical and laboratory evaluation of disease progression or response to treatment.
- Investigation of erythropoiesis and erythroblastosis in various experimental models.
Sample Types and Sensitivity
Typical kits accommodate plasma, serum, tissue lysates, and sometimes secretions. Sensitivity often allows detection in the low nanogram or picogram ranges, enabling identification of low-abundance biomarkers critical for early diagnosis.
In summary, the Erythroblastosis ELISA Kit is a valuable tool for sensitive and specific detection of markers relevant to erythroblastosis fetalis and related conditions. Its use facilitates early diagnosis, better understanding of disease mechanisms, and monitoring therapeutic efficacy.
